We seek to break through the limitations of current immunotherapies and achieve meaningful responses in patients. Our novel approach optimises the natural innate and adaptive immune pathways to reinvigorate the innate immunity of the tumor microenvironment for a comprehensive anti-tumor response. Our mission is to create immunotherapies and vaccines that deliver extraordinary benefits to patients. Our pipeline, underpinned by our revolutionary research in immune response, spans oncology and chronic viral infection, including sepsis and a booster COVID-19 vaccine. We are advancing cutting-edge science to surpass the limits of current checkpoint inhibitors and command an active innate immune response to improve the lives of more patients. Our pipeline is focused on impact creation, and includes NanoCherub™, our nanocomplex platform technology which is accelerating the creation of injectable and oral therapeutic and prophylactic vaccines.